Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF ULCERATIVE COLITIS IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN’S DISEASE AND COLITIS (GEDIIB)

2023; Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE); Linguagem: Inglês

10.1590/s0004-2803.2022005s1-03

1678-4219

Júlio Pinheiro Baima, Marcello Imbrizi, Adriana Ribas Andrade, Liliane Andrade CHEBLI, Marjorie Argollo, Natália Sousa Freitas Queiroz, Matheus Freitas Cardoso de Azevedo, Andréa Vieira, Márcia Henriques de Magalhães Costa, Renata de Sá Brito Fróes, Francisco Guilherme Cancela e Penna, Abel Botelho Quaresma, Adérson Omar Mourão Cintra Damião, Antônio Carlos Moraes, Carlos Henrique Marques dos Santos, Cristina Flores, Cyrla Zaltman, Eduardo García Vilela, Eloá Marussi Morsoletto, Francisco de Assis Gonçalves Filho, Genoile Oliveira Santana, Gilmara Pandolfo Zabot, José Miguel Luz Parente, Lígia Yukie Sassaki, Marco Zerôncio, Marta Brenner Machado, Ornella Sari Cassol, Paulo Gustavo Kotze, Rogério Serafim Parra, Sender Jankiel Miszputen, Cláudio Saddy Rodrigues Coy, Orlando Ambrogini, Júlio Maria Fonseca Chebli, Rogério Saad-Hossne,

Eosinophilic Esophagitis

Background: Inflammatory bowel diseases are immune-mediated disorders that include Crohn's disease (CD) and ulcerative colitis (UC). UC is a progressive disease that affects the colorectal mucosa causing debilitating symptoms leading to high morbidity and work disability. As a consequence of chronic colonic inflammation, UC is also associated with an increased risk of colorectal cancer. Objective: This consensus aims to provide guidance on the most effective medical management of adult patients with UC. Methods: A consensus statement was developed by stakeholders representing Brazilian gastroenterologists and colorectal surgeons (Brazilian Organization for Crohn's Disease and Colitis [GEDIIB]). A systematic review including the most recent evidence was conducted to support the recommendations and statements. All recommendations/statements were endorsed using a modified Delphi Panel by the stakeholders/experts in inflammatory bowel disease with at least 80% or greater consensus. Results and conclusion: The medical recommendations (pharmacological and non-pharmacological) were mapped according to the stage of treatment and severity of the disease onto three domains: management and treatment (drug and surgical interventions), criteria for evaluating the effectiveness of medical treatment, and follow-up/patient monitoring after initial treatment. The consensus targeted general practitioners, gastroenterologists and surgeons who manage patients with UC, and supports decision-making processes by health insurance companies, regulatory agencies, health institutional leaders, and administrators.